From hypercars to cruise missiles: Lukas Czinger on the future of US defense | E2292

What It Covers

This Week in Startups covers three distinct topics across 107 minutes: Lukas Czinger explains how Divergent Technologies uses AI-generated designs and 3D printing to manufacture cruise missile airframes at scale; cofounders of Outro Health detail the science of antidepressant tapering; and Jason and Lon analyze Meta's employee monitoring practices and a canceled Trump AI executive order.

Key Questions Answered

• •3D Printing Volume Threshold: Metal additive manufacturing becomes cost-competitive with traditional methods at approximately 10,000 units per year for defense-grade geometries. In automotive, where geometries are simpler and volumes reach millions, the crossover point sits in the high single-digit thousands. Above 30,000 automotive units annually, traditional casting typically wins on cost. Printing speeds have improved from 10 cubic centimeters per hour a decade ago to several hundred today, fundamentally shifting the economics of the technology.
• •Airframe Consolidation Economics: Divergent's AI-driven design process reduces a typical cruise missile airframe from roughly 200 discrete parts to fewer than 10. This consolidation delivers 20–30% reduction in mass, 20–30% increase in fuel volume, and up to 50% lower per-unit cost compared to traditionally manufactured equivalents. Fewer parts also means fewer failure points. A single Divergent 3D printer produces approximately 200 cruise missile airframes per year, meaning 100 printers yield roughly 20,000 airframes annually from one factory.
• •Hyperbolic Tapering Framework: When reducing antidepressant doses, the relationship between dose and brain effect follows a hyperbolic curve, not a straight line. Going from 5mg to 0mg produces roughly 20 times the neurological disruption of going from 20mg to 15mg, even though both represent a 5mg reduction. Outro Health's protocol reduces doses by equal increments of brain effect rather than equal milligram amounts, requiring compounded medications to reach doses far below standard tablet sizes available in pharmacies.
• •Antidepressant Withdrawal Misdiagnosis: Doctors routinely misidentify antidepressant withdrawal symptoms — panic attacks, insomnia, low mood — as relapse of the original condition, often before patients finish describing their symptoms. This misdiagnosis traps patients in a prescribing loop, returning them to medication they were attempting to discontinue. Long-term studies are absent; most clinical trials ran for only 8 weeks, yet approximately 20 million Americans have been on these drugs for 5 or more years, creating a significant evidence gap.
• •Chemical Imbalance Theory Lacks Evidence: Sixty years of research examining blood, cerebrospinal fluid, and brain tissue has not confirmed that depressed individuals have lower serotonin than healthy controls. The hypothesis originated in the 1960s and was amplified by pharmaceutical marketing. By age 45, roughly 70% of people will experience clinical depression or anxiety, making a brain-defect explanation statistically implausible. The number of stressful life events a person experiences is a stronger predictor of depression onset than any identified neurochemical marker.
• •Defense Procurement Incentive Misalignment: Traditional cost-plus defense contracts pay suppliers a fixed percentage above production cost, eliminating financial incentive to reduce cost or accelerate timelines. A supplier earning 10% margin on a $1M missile earns less if the missile costs $250K. Startup neo-primes operating on fixed-price or performance-based contracts invert this incentive, rewarding speed and efficiency. This structural shift, combined with venture capital entering defense, has compressed development timelines from decades to months for certain munitions programs.
• •Antidepressant Side Effect Profile: Beyond emotional numbing reported by approximately three-quarters of users, SSRIs produce a documented cluster of side effects that users rarely attribute to the medication after years of use: daytime fatigue, disrupted nighttime sleep, impaired concentration, impaired memory, weight gain, and sexual dysfunction affecting desire, erection, and orgasm in both sexes. For a subset of patients, sexual dysfunction persists after discontinuation — a condition researchers are beginning to study. Researchers are also investigating a potential correlation between long-term SSRI use and asexuality.